{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:23:26Z","timestamp":1791829406575,"version":"4.3.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.eururo.2012.10.016","type":"journal-article","created":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T17:00:52Z","timestamp":1352221252000},"page":"283-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":387,"title":["Efficacy and Tolerability of Mirabegron, a \u03b23-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European\u2013Australian Phase 3 Trial"],"prefix":"10.1016","volume":"63","author":[{"given":"Vik","family":"Khullar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Amarenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier C.","family":"Angulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cambronero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil","family":"H\u00f8ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Milsom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Radziszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Rechberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Boerrigter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Drogendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Wooning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chapple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2012.10.016_bib0005","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.10.016_bib0010","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.10.016_bib0015","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1464-410X.2009.08427.x","article-title":"The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study","volume":"104","author":"Coyne","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.10.016_bib0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.10.016_bib0025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1442-2042.2008.02177.x","article-title":"Clinical guidelines for overactive bladder","volume":"16","author":"Yamaguchi","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2012.10.016_bib0030","first-page":"291","article-title":"Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan","volume":"14","author":"D'Souza","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.eururo.2012.10.016_bib0035","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.10.016_bib0040","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00042307-200307000-00004","article-title":"Recent developments in the management of detrusor overactivity","volume":"13","author":"Kumar","year":"2003","journal-title":"Curr Opin Urol"},{"issue":"5Suppl 1","key":"10.1016\/j.eururo.2012.10.016_bib0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0090-4295(01)01635-1","article-title":"\u03b23-adrenoceptors in human detrusor muscle","volume":"59","author":"Yamaguchi","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.10.016_bib0050","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2012.05.053","article-title":"A multicenter, double-blind, randomized, placebo-controlled trial of the \u03b23-adrenoceptor agonist solabegron for overactive bladder","volume":"62","author":"Ohlstein","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.10.016_bib0055","doi-asserted-by":"crossref","unstructured":"Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. In press. http:\/\/dx.doi.org\/10.1111\/j.1464-410X.2012.11023.x.","DOI":"10.1111\/j.1464-410X.2012.11023.x"},{"key":"10.1016\/j.eururo.2012.10.016_bib0060","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00228-010-0917-z","article-title":"Low persistence of anticholinergic drug use in Sweden","volume":"67","author":"Linn\u00e9r","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.eururo.2012.10.016_bib0065","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00345-010-0513-y","article-title":"The effect of tolterodine 4 and 8mg on the heart rate variability in healthy subjects","volume":"28","author":"Schiffers","year":"2010","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2012.10.016_bib0070","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1074248408325404","article-title":"Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants \u226550 years","volume":"13","author":"Olshansky","year":"2008","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.eururo.2012.10.016_bib0075","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1464-410X.2007.07100.x","article-title":"Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations","volume":"100","author":"Andersson","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.10.016_bib0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2288-9-55","article-title":"A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder","volume":"9","author":"Lee","year":"2009","journal-title":"BMC Med Res Methodol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812012353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812012353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:04:54Z","timestamp":1759583094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283812012353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0302283812012353"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2012.10.016","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717969189.793469637","asserted-by":"object"}]},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Tolerability of Mirabegron, a \u03b23-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European\u2013Australian Phase 3 Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2012.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}